Roche's Lunsumio combo met its primary endpoint in Phase III follicular lymphoma trial, beating rituximab plus lenalidomide ...

BH-30643 achieves 45% response rate in osimertinib-resistant NSCLC patients with C797S mutations, showing 88% disease control ...

Coya Therapeutics enrolls 100th patient in ALSTARS trial of COYA 302 for ALS, reaching a key recruitment milestone for the ...

Mayo Test Drive completed at 97.5% across MCI, mild, and moderate dementia patients, here's what that means for Alzheimer's ...

Summit Therapeutics presents updated overall survival results for ivonescimab in EGFR-mutated NSCLC from the Phase III ...

Risk-based quality management requires linking quality plans to data management protocols. EU regulators now expect ...

TRUTAKNA meets all endpoints in Phase 3 IgA Nephropathy Trial final analysis, confirming eGFR stabilization and disease ...

The Lancet calls out "hard to reach" as a stigmatizing label. For clinical ops, it's a site selection failure with a ...

Med-Gemini scores 91% on MedQA. OpenAI's o1-preview hits 96%. Neither number tells you what happens when the algorithm meets ...

Pulse Biosciences closes enrollment in PRECISE-BTN Thyroid Nodule trial with first patient completing follow-up, positioning for primary dataset readout within ...

Professor Peter George, Pulmonologist at the Royal Brompton and Senior Medical Director at Brainomix, on why quantitative CT ...

Sionna advances SION-451 and SION-2222 into Phase 2a trial to test dual-corrector approach for Trikafta-resistant CF patients ...